Migraine prophylaxis refers to treatments taken on a regular schedule to reduce how often migraines strike, how severe they are, and how much they interfere with daily life. It is generally considered when someone experiences four or more migraine days per month, though guidelines also factor in disability level and how well acute treatments are working. The field has expanded dramatically over the past decade, moving from repurposed blood pressure and seizure medications to drugs designed specifically for migraine biology, and the options now span daily pills, monthly injections, wearable nerve stimulators, and behavioral therapies.
Who Should Consider Preventive Treatment
There is no single migraine-day threshold that automatically triggers a preventive prescription. Updated practice guidelines from the American Academy of Neurology and the American Headache Society emphasize shared decision-making, weighing migraine frequency and disability against the burden of adding a daily or monthly medication.1Neurology. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations In practice, most clinicians bring up prophylaxis when migraines hit at least four days a month, when acute medications stop working reliably, when someone is overusing painkillers or triptans, or when attacks are unusually prolonged or debilitating even if infrequent. Coexisting conditions also shape the decision. A person with migraine plus high blood pressure may benefit from a beta-blocker that addresses both. Someone with migraine and depression might do well on an antidepressant that also lowers headache frequency. The guideline framework encourages matching the preventive drug to the whole clinical picture rather than treating migraine in isolation.
Traditional Oral Preventives
For decades, the backbone of migraine prevention consisted of drugs originally developed for other conditions. None were designed with migraine in mind, but randomized trials showed they could meaningfully reduce attack frequency.
Beta-Blockers
Propranolol and metoprolol are the best-studied beta-blockers for migraine. Both are lipophilic, meaning they cross into the brain more readily than water-soluble beta-blockers, and both carry a top-tier recommendation for migraine prevention.2PubMed. β-blockers: Their new life from hypertension to cancer and migraine The evidence supporting their effectiveness is extensive, though they are often prescribed at doses that are lower than what the trials actually tested, which can make them seem less effective than they are.3PubMed. Beta-Blockers for Migraine Prevention: a Review Article Common side effects include fatigue, exercise intolerance, and cold hands, which can be dealbreakers for active people. They are generally avoided in those with asthma or low heart rate.
Antiepileptic Drugs
Topiramate stands out among seizure medications because it works through multiple brain pathways, which may explain why it succeeds where more narrowly targeted anticonvulsants do not.4PubMed. Topiramate in Migraine Prevention: A 2016 Perspective Trials show it reduces migraine frequency, cuts acute medication use, and improves quality of life in both episodic and chronic migraine, including people with medication overuse headache.5PubMed Central. Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference The tradeoffs are real, though. Cognitive side effects like word-finding difficulty and mental fogginess are commonly reported, and the drug can cause tingling in the hands and feet, appetite suppression, and kidney stones. It also carries serious risks during pregnancy, making reliable contraception essential for women of childbearing age.
Antidepressants
Amitriptyline, a tricyclic antidepressant, and venlafaxine, a serotonin-norepinephrine reuptake inhibitor, both have Level B evidence (meaning “probably effective”) for migraine prevention.6Neurology India. Preventive Oral Treatment of Episodic Migraine: An Overview Amitriptyline is especially useful when migraine coexists with insomnia or tension-type headache, since its sedating properties can be a benefit rather than a nuisance. One randomized trial found venlafaxine outperformed amitriptyline on several measures of attack reduction.7Biomedicine and Pharmacotherapy / Biomedical and Pharmacology Journal. Efficacy and Safety of Venlafaxine Versus Amitriptyline in Decreasing Severity and Frequency of Migraine Attacks In practice, amitriptyline’s drowsiness and weight gain push many patients toward venlafaxine, which tends to be better tolerated at the lower doses used for headache prevention. Selective serotonin reuptake inhibitors like fluoxetine have weaker evidence and are not typically first-line choices.
CGRP Monoclonal Antibodies
The discovery that calcitonin gene-related peptide (CGRP) plays a central role in migraine led to the first class of drugs built specifically for migraine prevention. CGRP is a signaling molecule released by nerve fibers around the brain’s blood vessels, and during a migraine it floods the system, driving inflammation and pain. Blocking CGRP or its receptor short-circuits that process.8PubMed. Calcitonin Gene-Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class
Four monoclonal antibodies are now approved for migraine prevention: erenumab, fremanezumab, galcanezumab, and eptinezumab. A systematic review found all four to be safe and effective, and noted that combining them with onabotulinumtoxinA may provide additional benefit.9PubMed Central. Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review A network meta-analysis comparing different doses found that galcanezumab 120 mg and eptinezumab 300 mg delivered the greatest reductions in monthly migraine days for chronic migraine, while fremanezumab had the highest proportion of patients achieving at least a 50 percent drop in headache days.10Clinical Psychopharmacology and Neuroscience. Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis Overall, CGRP antibodies have a much cleaner side-effect profile than the older oral preventives, which is a significant practical advantage.11PubMed. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications
These medications are given as self-administered monthly injections (or, for eptinezumab, quarterly intravenous infusions). The convenience is high, but so is the cost, which brings its own set of challenges covered later in this article.
Oral CGRP Receptor Antagonists (Gepants)
Atogepant and rimegepant are small-molecule pills that block the CGRP receptor, giving people a targeted preventive they can take by mouth. In its pivotal trial, atogepant at the 60 mg dose reduced monthly migraine days by about 4.2 from baseline, compared with 2.5 for placebo, a difference of roughly 1.7 fewer migraine days attributable to the drug itself.12PubMed. Atogepant for the Preventive Treatment of Migraine Side effects were mostly gastrointestinal: constipation in about 7 percent and nausea in about 5 percent of people taking atogepant. Rimegepant, taken every other day, reduced migraine days by about 0.8 more than placebo by weeks 9 through 12, with adverse events comparable to placebo.13The Lancet. Safety and efficacy of rimegepant for the preventive treatment of migraine Rimegepant has the unusual advantage of being approved for both prevention and acute treatment, so a single medication can serve double duty.
OnabotulinumtoxinA for Chronic Migraine
OnabotulinumtoxinA, widely known by its brand name Botox, is approved specifically for chronic migraine, defined as 15 or more headache days per month. The treatment involves injections across 31 to 39 sites in seven muscles of the head and neck, repeated every 12 weeks. It works by blocking the release of pain-signaling molecules from sensory nerve endings in those muscles, reducing the flood of pain signals reaching the brain and dampening the overactive nerve circuits believed to drive chronic migraine.14PubMed Central. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review Research also suggests that the toxin travels along sensory nerve fibers to deeper relay stations in the brain, where it continues to suppress pain processing.15PubMed Central. Therapeutic use of botulinum toxin in migraine: mechanisms of action The treatment is generally well tolerated; the most common complaints are injection-site pain and occasional neck weakness. It is not effective for episodic migraine (fewer than 15 headache days per month), which is an important distinction many patients are unaware of.
Non-Drug and Behavioral Approaches
Prevention does not have to come from a prescription. Behavioral therapies, including cognitive behavioral therapy, relaxation training, and mindfulness-based programs, have shown they can reduce migraine frequency and related disability.16PubMed Central. Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-Analysis A large systematic review covering 50 adult trials found low but positive evidence that CBT, relaxation training, and mindfulness-based therapies each reduce headache attacks, while education programs that target behavior may improve migraine-related disability.17PubMed Central. Behavioral interventions for migraine prevention: A systematic review and meta-analysis Evidence for biofeedback and hypnotherapy was insufficient to draw firm conclusions. These approaches are most powerful when layered on top of medication, not treated as all-or-nothing alternatives, though they are particularly valuable for people who cannot take drugs because of pregnancy, other health conditions, or intolerance.
Sleep-focused behavioral interventions deserve special mention. Migraine and poor sleep overlap so heavily that treating one often improves the other. A meta-analysis found that psychological sleep treatments produced significant reductions in headache frequency, intensity, and disability, while simultaneously improving sleep quality and efficiency.18PubMed Central. Psychological Sleep Interventions for Migraine and Tension-Type Headache: A Systematic Review and Meta-Analysis For someone whose migraines cluster around disrupted sleep, structured sleep hygiene or cognitive behavioral therapy for insomnia can be a high-yield, low-risk starting point.
Neuromodulation Devices
Several wearable devices now offer a drug-free route to migraine prevention. The best evidence exists for supra-orbital transcutaneous electrical nerve stimulation, which delivers mild electrical pulses through a headband worn over the forehead. A randomized sham-controlled trial found that 20 minutes of daily use reduced monthly migraine days from about 7 to about 5, with a 50 percent responder rate roughly three times higher than in the sham group.19PubMed. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial A broader systematic review and meta-analysis found small to medium effect sizes for supra-orbital stimulation, percutaneous electrical nerve stimulation, and high-frequency repetitive transcranial magnetic stimulation applied over the motor cortex.20PubMed Central. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials These devices have very few side effects, mostly mild tingling or local discomfort. Their main drawbacks are modest effect sizes compared with the strongest medications and out-of-pocket cost, since insurance coverage varies widely.
Supplements
Magnesium, riboflavin (vitamin B2), and coenzyme Q10 are the supplements with the most clinical attention for migraine prevention. A double-blind multicenter trial tested a combination of all three against placebo. The supplement reduced migraine days from about 6.2 to 4.4 over three months, but this drop did not reach statistical significance for migraine frequency alone. It did significantly reduce peak pain intensity and improve scores on a headache impact questionnaire compared with placebo.21PubMed Central. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial The takeaway is that these supplements may make migraines milder and less disabling rather than dramatically cutting their number. Given their low risk profile, many headache specialists suggest them as an add-on or as a first step for people with infrequent attacks who want to avoid prescription drugs.
Migraine Prevention in Children
Preventing migraines in children and adolescents is genuinely difficult. The American Academy of Neurology’s pediatric guideline acknowledges that most randomized controlled trials of preventive medications in children fail to beat placebo.22PubMed Central. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention A landmark trial published in the New England Journal of Medicine tested amitriptyline, topiramate, and placebo head-to-head in children and teens. About 52 percent of the amitriptyline group and 55 percent of the topiramate group met the primary endpoint, but so did 61 percent of the placebo group, meaning neither drug outperformed a sugar pill.23PubMed Central. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine
This does not mean children’s migraines are imaginary. Part of the explanation is an extraordinarily high placebo response in younger patients. Placebo response rates in pediatric migraine trials approach 50 percent or higher, compared with roughly 35 percent in adult trials.24PubMed Central. Harnessing the Placebo effect in Pediatric Migraine Clinic That makes it exceptionally hard for any active drug to demonstrate superiority in a clinical trial, and it suggests that the supportive elements of medical care, such as regular visits, reassurance, and structured attention to triggers, are themselves therapeutic in young people. In clinical practice, behavioral interventions, sleep hygiene, and lifestyle counseling tend to be the first-line approach for pediatric migraine prevention, with medications reserved for severe cases.
Prevention During Pregnancy and Breastfeeding
Pregnancy complicates migraine management considerably, since many preventive drugs carry teratogenic risks or lack safety data. Guidelines recommend prioritizing non-pharmacological strategies: lifestyle changes, behavioral therapy, and potentially non-invasive neuromodulation.25PubMed. Migraine management during pregnancy, breastfeeding and in women planning pregnancy When migraines are disabling enough that leaving them untreated poses its own risks (poor nutrition, dehydration, inability to function), some medications can be considered, but the choice requires careful weighing of benefit and harm. Topiramate is specifically contraindicated. During breastfeeding, the focus shifts to minimizing how much drug passes into breast milk while keeping the mother’s migraines controlled.
Why People Stop Treatment
A common frustration in headache medicine is that many people start a preventive medication and then abandon it before giving it a fair trial. A systematic review of adherence data found that persistence with oral preventives drops sharply over time: roughly 55 to 57 percent of people were still taking topiramate or amitriptyline after four to six months, while propranolol did somewhat better at 77 percent.26PubMed Central. Systematic review of migraine prophylaxis adherence and persistence By 12 months, persistence across oral preventives in observational studies ranged from about 7 to 55 percent. Side effects were the most commonly cited reason for stopping, accounting for roughly a quarter of topiramate discontinuations and about 17 percent for amitriptyline.
This matters beyond the individual experience. A large real-world study found that only about 30 percent of patients who started preventive treatment were still on it at 12 months. Those who stopped treatment needed more primary care visits and took more sick days, and their annual healthcare costs were over €600 higher than those who persisted.27PubMed Central. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study The implication is that finding a tolerable medication matters as much as finding an effective one. A drug that works on paper but makes someone feel foggy, exhausted, or nauseated will not work in practice because people will not keep taking it.
When Standard Treatments Fail
Headache specialists now distinguish between resistant and refractory migraine. Resistant migraine is defined by failure of three or more classes of preventive drugs. Refractory migraine means all available classes have been tried without success.28The Lancet eBioMedicine. Resistant and refractory migraine: a review of current knowledge and future directions Managing refractory migraine is often frustrating for everyone involved. A multidisciplinary approach becomes essential, and clinicians are advised to avoid piling on more failed treatment attempts, instead focusing on quality of life and realistic goals.
One strategy gaining traction is combination therapy. Retrospective studies and case series have shown benefit from pairing onabotulinumtoxinA with a CGRP monoclonal antibody.29The Lancet eBioMedicine. Resistant and refractory migraine: a review of current knowledge and future directions The rationale is that onabotulinumtoxinA acts mainly at peripheral nerve endings while CGRP antibodies work further along the pain pathway, creating a dual blockade. Early real-world evidence supports this: patients on combination therapy showed greater reductions in monthly migraine days, headache intensity, and disability scores compared with those on either treatment alone.30Confinia Cephalalgica. PO-91 | Real-world evidence of CGRP dual blockade Large randomized trials are still needed, but for people who have run out of options, this combination is increasingly seen as a reasonable next step.
The Cost Problem
The targeted therapies have a pricing problem. Generic beta-blockers, topiramate, and amitriptyline cost pennies per day. CGRP monoclonal antibodies run several thousand dollars a year. And the oral gepants are even more expensive on a per-day basis. A cost-effectiveness analysis from a U.S. societal perspective found that both atogepant and rimegepant exceeded widely accepted cost-effectiveness thresholds for episodic migraine prevention when compared with placebo. Atogepant came in at over $450,000 per quality-adjusted life-year, and rimegepant at over $890,000.31PubMed. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine The CGRP monoclonal antibody erenumab fares better in the chronic migraine population, where the economic argument is stronger because chronic migraine imposes heavier costs from lost productivity and healthcare utilization. But for episodic migraine, erenumab’s value is uncertain unless lost work time is factored in.32PubMed. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine
In practical terms, this means most insurers require patients to try and fail one or more generic oral preventives before approving a CGRP-targeted therapy, a process called step therapy. For patients, this adds months of trial and error. For the healthcare system, it is a reasonable cost-containment strategy, but it can feel callous when someone is suffering through a medication that makes them feel terrible just to check a box.
Emerging Targets Beyond CGRP
CGRP is not the only signaling molecule involved in migraine. Pituitary adenylate cyclase-activating polypeptide, or PACAP, is another neuropeptide linked to migraine pathogenesis. A phase II trial has already provided evidence that a monoclonal antibody targeting PACAP is effective for migraine prevention, opening a potentially complementary pathway for people who do not respond to CGRP-targeted drugs.33Nature Reviews Neurology. Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine Meanwhile, researchers are working on biomarkers that might predict which patients will respond to which treatments before months of trial and error. CGRP levels and other biological factors tied to the brain’s pain-processing system are being explored, though confounders like age, diet, and metabolic health make it hard to settle on a reliable test.34PubMed Central. Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings Machine learning models that incorporate clinical features, comorbidities, and eventually genomic data are also under development, though current models remain too imprecise for clinical use.35PubMed. Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models The long-term vision is a world where a headache specialist can look at a patient’s biological profile and say with some confidence which drug class is most likely to work, rather than the current approach of educated guessing and sequential trial.